Buscar
Grifols SA
GRFSAñadir a la lista de seguimiento
7.310USD
-0.090-1.22%
Cierre 09-18 16:00（ET）
1.88BCap. mercado
9.40P/E TTM
Más Datos de Grifols SA Compañía
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Perfil de Grifols SA
Símbolo de cotizaciónGRFS
Nombre de la empresaGrifols SA
Fecha de salida a bolsaMay 17, 2006
Director ejecutivoAbia (Jose Ignacio)
Número de empleados23833
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 17
DirecciónParque Empresarial Can Sant Joan
CiudadSANT CUGAT DEL VALLES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSpain
Código postal08174
Teléfono34935710000
Sitio Webhttps://www.grifols.com/
Símbolo de cotizaciónGRFS
Fecha de salida a bolsaMay 17, 2006
Director ejecutivoAbia (Jose Ignacio)
Ejecutivos de Grifols SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Mr. Tomas Daga Gelabert
Mr. Tomas Daga Gelabert
Other External Director
Other External Director
--
--
Mr. Raimon Grifols Roura
Mr. Raimon Grifols Roura
Vice Chairman of the Board, Proprietary Director
Vice Chairman of the Board, Proprietary Director
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Assistant Secretary of the Board of Directors
Non-Member Assistant Secretary of the Board of Directors
--
--
Mr. Ignacio Ramal Subira
Mr. Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Management
Chief Internal Audit & Enterprise Risk Management
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Grifols SA?
Los cinco principales accionistas de Grifols SA son: Mr. Enrique De La Torre
¿Cuántas instituciones poseen acciones de Grifols SA (GRFS)?
A fecha de 2026Q1, 346 instituciones poseen acciones de Grifols SA, con un valor de mercado combinado de aproximadamente 148.94M, lo que representa el 57.68% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -8688154.00.